

159. (New) The pharmaceutical composition of claim 154, wherein the lipophilic substituent has from 12 to 24 carbon atoms.

160. (New) The pharmaceutical composition of claim 154, wherein the insulin derivative is in the form of a hexamer.

161. (New) A method of treating diabetes in a patient in need of such a treatment, said method comprising administering to the patient a therapeutically effective amount of a pharmaceutical composition of claim 154.

162. (New) A method of treating diabetes in a patient in need of such a treatment, said method comprising administering to the patient a therapeutically effective amount of a pharmaceutical composition of claim 157.

Remarks

Following entry of the above amendments to the claims, claims 89-131 and 146-162 are pending in this application.

Newly added claims 154-162 are based on claims 132-139 which were inadvertently cancelled in the Amendment filed September 19, 2002. Claims 154-162 ultimately depend from allowed claim 89 and find clear support inter alia in the originally filed claims.

As required by 37 C.F.R. 1.121, a "marked-up" copy of the amended claims is appended to this Amendment.

REJECTION UNDER 35 U.S.C. § 112, SECOND PARAGRAPH


it is allegedly unclear whether the insulin or insulin analogue is to be administered in addition to the insulin derivative of claim 147.

In response, Applicants state that the insulin or insulin analogue recited in claims 150 and 153 is to be administered in addition to the insulin derivative of claim 147. Accordingly, withdrawal of this rejection is respectfully requested.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted, .

Date: April 14, 2003


Richard W. Bork, Reg. No. 36,459
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800



23650

PATENT TRADE MARK OFFICE



"Marked-up" Copy Of Amendments To The Claims

147. (Amended) A pharmaceutical composition which is an aqueous solution, said composition comprising (a) the insulin derivative of claim 146, (b) an isotonic agent, (c) a preservative and (d) a buffer.

150. (Amended) The pharmaceutical composition of claim 147, said composition further comprising an insulin or an insulin analogue which has a rapid onset of action.

152. (Amended) A method of treating diabetes in a patient in need of such a treatment, said method comprising administering to the patient a therapeutically effective amount of a pharmaceutical composition of claim 147.

153. (Amended) A method of treating diabetes in a patient in need of such a treatment, said method comprising administering to the patient a therapeutically effective amount of a pharmaceutical composition of claim 150.

RECEIVED

TECHNICAL STAFF